Search filters

List of works by Paul Hamlin

A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma

scientific article published on 18 February 2015

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

scientific article published on 4 August 2008

A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma

scientific article

A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.

scientific article published on 27 May 2009

A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.

scientific article

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 15 February 2019

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

scientific article published on 3 April 2003

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients

scientific article

Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP 53 alterations

scientific article published on 11 December 2018

Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary

scientific article

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

scientific article

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

scientific article published on 25 July 2016

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

scientific article published on 9 August 2005

Central nervous system involvement in T-cell lymphoma: A single center experience

scientific article published on 04 April 2016

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma

scholarly article by Anita Kumar et al published April 2019 in Haematologica

Development of a Geriatric Service in a Cancer Center: Lessons Learned

scientific article published on February 2017

Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper.

scientific article published on 07 December 2014

Distress in older patients with cancer

scientific article

Do six or eight cycles work better with CHOP-14 and rituximab?

scientific article published in September 2008

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

scientific article published on 08 January 2019

Evolving Treatment Paradigms for Primary Mediastinal Diffuse Large B-Cell Lymphoma

scientific article published on 05 May 2014

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma

scientific article published on 01 July 2020

Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma

scientific article

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma

scientific article published on September 2015

High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging

scientific article published on 18 January 2010

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

scientific article published on 15 June 2017

Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice

scientific article published on 14 August 2007

Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma

scientific article published on July 2006

Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma

scientific article

Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy

scientific article published on 26 October 2007

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

scientific article published on 12 June 2018

Is Maintenance Rituximab Now Ready for PRIMA-Time?

scientific article published on 01 November 2010

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

scientific article

Meta-analysis: Making sense of maintenance rituximab?

scientific article published on 01 September 2009

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma

article

New drugs for the treatment of advanced-stage diffuse large cell lymphomas

scientific article published on October 2006

New strategies in radioimmunotherapy for lymphoma

scientific article

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

scientific article published on 19 December 2011

Nuances in the Management of Aggressive Lymphomas.

scientific article published in April 2017

Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma

scientific article published on 23 June 2016

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

scientific article published on 01 October 2020

Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant

scientific article published on 15 June 2018

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

scientific article published on 13 February 2015

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

scientific article published on May 2014

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

scientific article

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

scientific article published on 20 May 2019

Personalizing therapy for older adults with lymphoid malignancies: options and obstacles

scientific article published on January 2014

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

scientific article

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

scientific article

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma

scientific article published on 23 February 2011

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

scientific article

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

scientific article

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma

scientific article

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

scientific article published on 3 August 2009

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

scientific article

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

scientific article published in November 2007

Primary lymphoma of the breast: a case of marginal zone B-cell lymphoma

scientific article published on 01 August 2004

Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.

scientific article

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

scientific article published on 5 September 2017

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

scientific article published in November 2004

Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma

scientific article published on 30 December 2015

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

scientific article

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma

scientific article published on 8 March 2010

Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.

scientific article

Testis-Isolated Mantle Cell Lymphoma: A Unique Case

scientific article published on 08 September 2011

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

scientific article

The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).

scientific article published on 12 January 2009

The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.

scientific article published on 12 January 2009

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

scientific article

Treatment of Rosai–Dorfman disease with oral bexarotene: a case series

scientific article published on 19 November 2018

Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis

scientific article

Paulina is supported by:

About Paulina

Help